SAN JOSE, CA, USA I5, 2025 I BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditionally “hard-to-drug” targets, announced today a strategic collaboration and ...

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...

BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...